References
- Boehringer Ingelheim Pharmaceuticals, IncDabigatran [package insert]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc2012
- LakkireddyDReddyYMDi BiaseLFeasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registryJ Am Coll Cardiol201259131168117422305113
- WinkleRAMeadRHEngelGKongMHPatrawalaRAThe use of dabigatran immediately after atrial fibrillation ablationJ Cardiovasc Electrophysiol201223326426821955008
- McAvoyTJThe biologic half-life of heparinClin Pharmacol Ther1979253372379761447
- WachsmanMMielkeCHJrHayesJABakerDThe use of time step simulations and difference equations (TSSADEQ) in modeling heparin pharmacokineticsJ Clin Pharmacol200040101121112811028251
- BrunetPSimonNOprisAPharmacodynamics of unfractionated heparin during and after a hemodialysis sessionAm J Kidney Dis200851578979518436089
- CannonCPDingemanseJKleinbloesemCHJannettTCurryKMValckeCPAutomated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteersCirculation19999967517569989959
- BoneuBCaranobeCSiePPharmacokinetics of heparin and low molecular weight heparinBaillieres Clin Haematol1990335315442176903
- KimJSSheFJongnarangsinKDabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillationHeart Rhythm201310448348923237911
- KonduruSVCheemaAAJonesPLiYRamzaBWimmerAPDifferences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs patients on uninterrupted warfarinJ Interv Card Electrophysiol2012353277284 [discussion 284]23015216